An aggressive form of MOGAD treated with aHSCT: A case report.
Elvira SbragiaGiacomo BoffaRiccardo VaraldoAnna Maria RaiolaAnna GhisoMassimiliano GambellaLuana BenedettiEmanuele AngelucciMatilde InglesePublished in: Multiple sclerosis (Houndmills, Basingstoke, England) (2023)
In a patient affected by aggressive, treatment-refractory MOGAD, aHSCT resulted as safe and was able to suppress disease-activity for over 2 years.